OptimizeRx Corporation (OPRX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
OptimizeRx Corporation (OPRX) trades at $6.38 with AI Score 87/100 (Grade A+). OptimizeRx Corporation provides digital health solutions, connecting life sciences companies with healthcare providers and patients. Market cap: $120M, Sector: Healthcare.
Price as of Jul 27, 2026 · Last analyzed: May 10, 2026OPRX stock analysis for 2026: Analysts have set a consensus price target of $17.00 for OptimizeRx Corporation, suggesting 166.2% upside from the current price of $6.38. The AI MoonshotScore is 87/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
OPRX: 3/3 scored disciplines lean bullish. Dominant signal: Growth Durability strong.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
OptimizeRx Corporation (OPRX) Healthcare & Pipeline Overview
OptimizeRx Corporation operates as a digital health technology company, delivering solutions that streamline communication between pharmaceutical manufacturers, healthcare providers, and patients. Their focus on financial messaging, patient support, and brand awareness positions them within the evolving healthcare information services sector, leveraging technology to improve patient outcomes and medication adherence.
What Is the Investment Thesis for OPRX?
OptimizeRx Corporation operates in the growing digital health market, connecting pharmaceutical companies with healthcare providers and patients. With a market capitalization of $120M and a P/E ratio of 16.3, the company demonstrates profitability with a 4.7% profit margin and a strong 63.3% gross margin. Key value drivers include the increasing adoption of digital health solutions by pharmaceutical companies and healthcare providers, as well as the growing need for improved medication adherence and patient engagement. Growth catalysts include expanding the reach of their Mobile Health Messenger platform and leveraging their data analytics capabilities to provide more targeted and personalized patient support. Potential risks include increasing competition in the digital health space and regulatory changes affecting the pharmaceutical industry. The company's beta of 1.28 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
OPRX Key Highlights
- Market capitalization of $120M indicates the company's current valuation in the market.
- P/E ratio of 16.3 suggests investors are willing to pay $23.42 for every dollar of earnings.
- Profit margin of 4.7% demonstrates the company's ability to generate profit from its revenue.
- Gross margin of 63.3% indicates the company's efficiency in managing production costs.
- Beta of 1.28 suggests the stock is more volatile than the market.
Who Are OPRX's Competitors?
OPRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ONVVF Oneview Healthcare PLC | $0.16 | +0.00% | $123M | 60 |
| AUGX Augmedix, Inc. | $2.35 | -0.21% | $116M | 58 |
| CCLD CareCloud, Inc. | $2.23 | +0.45% | $94.8M | 79 |
| VPAHF Volpara Health Technologies Limited | $0.74 | +36.63% | $188M | 60 |
| SUSRF Surgical Science Sweden AB (publ) | $4.00 | +0.00% | $204M | 55 |
| SPOK Spok Holdings, Inc. | $10.81 | +2.08% | $226M | 83 |
| SMFR Sema4 Holdings Corp. | $0.31 | +26.78% | $246M | 60 |
| DLHTF Dialogue Health Technologies Inc. | $3.79 | +0.59% | $255M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OPRX's Key Strengths?
- Established presence in the digital health technology space.
- Strong relationships with pharmaceutical manufacturers and healthcare providers.
- Proprietary technology platform for delivering digital health solutions.
- HIPAA-compliant data security and privacy practices.
What Are OPRX's Weaknesses?
- Relatively small market capitalization compared to larger competitors.
- Dependence on the pharmaceutical industry for revenue.
- Limited geographic reach outside of the United States.
- Potential for regulatory changes affecting the pharmaceutical industry.
What Could Drive OPRX Stock Higher?
- Expansion of the Mobile Health Messenger platform to new therapeutic areas.
- Potential partnerships with healthcare providers to integrate OptimizeRx's solutions into EHR systems.
- Increased adoption of digital health technologies by pharmaceutical companies and healthcare providers.
- Development and launch of new patient engagement solutions.
- Leveraging data analytics capabilities to provide more targeted and personalized patient support.
What Are the Key Risks for OPRX?
- Increasing competition in the digital health technology space.
- Potential for data breaches and security vulnerabilities.
- Changes in healthcare regulations and reimbursement policies.
- Dependence on the pharmaceutical industry for revenue.
- Economic downturn affecting the pharmaceutical industry.
What Are the Growth Opportunities for OPRX?
- Expansion into new therapeutic areas: OptimizeRx can expand its reach by targeting new therapeutic areas and developing specialized solutions for specific patient populations. The market for digital health solutions in chronic diseases, such as diabetes and cardiovascular disease, is particularly large and growing. By developing tailored programs and messaging for these areas, OptimizeRx can attract new pharmaceutical clients and increase its revenue. This expansion can be achieved within the next 1-2 years, leveraging the existing platform and infrastructure.
- Geographic expansion: OptimizeRx can expand its geographic reach by targeting new markets outside of the United States. The demand for digital health solutions is growing globally, particularly in countries with aging populations and increasing healthcare costs. By partnering with local healthcare providers and pharmaceutical companies, OptimizeRx can establish a presence in these markets and tap into new revenue streams. This expansion could begin within the next 2-3 years, starting with pilot programs in select countries.
- Enhanced data analytics capabilities: OptimizeRx can enhance its data analytics capabilities to provide more targeted and personalized patient support. By leveraging data on patient demographics, medication history, and adherence patterns, the company can develop customized messaging and interventions that are more likely to improve patient outcomes. This requires investment in data science and analytics infrastructure, but the potential return on investment is significant. The development and implementation of these enhanced capabilities can be achieved within the next 1-2 years.
- Partnerships with healthcare providers: OptimizeRx can strengthen its relationships with healthcare providers by offering them new tools and resources to improve patient care. This could include integrating its platform with electronic health record (EHR) systems, providing access to clinical decision support tools, and offering training and education programs for healthcare professionals. By becoming a trusted partner to healthcare providers, OptimizeRx can increase its market share and improve its brand reputation. These partnerships can be developed and expanded over the next 1-3 years.
- Development of new patient engagement solutions: OptimizeRx can develop new patient engagement solutions that go beyond medication adherence and address other aspects of patient health and well-being. This could include developing mobile apps for tracking symptoms, providing access to telehealth services, and offering personalized health coaching. By expanding its offerings to address a broader range of patient needs, OptimizeRx can attract new customers and increase its revenue. The development and launch of these new solutions can be phased in over the next 2-4 years.
What Opportunities Does OPRX Have?
- Expansion into new therapeutic areas and geographic markets.
- Development of new patient engagement solutions.
- Partnerships with healthcare providers and other healthcare organizations.
- Increased adoption of digital health technologies by pharmaceutical companies and healthcare providers.
What Threats Does OPRX Face?
- Increasing competition in the digital health technology space.
- Potential for data breaches and security vulnerabilities.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturn affecting the pharmaceutical industry.
What Are OPRX's Competitive Advantages?
- Established relationships with pharmaceutical manufacturers and healthcare providers.
- Proprietary technology platform for delivering digital health solutions.
- HIPAA-compliant data security and privacy practices.
- Integration with electronic medical record (EMR) and e-prescribing (eRx) systems.
What Does OPRX Do?
Founded in 2006, OptimizeRx Corporation has evolved into a key player in the digital health technology space. The company provides a suite of solutions designed to connect life sciences organizations, healthcare providers, and patients, aiming to improve medication adherence, streamline communication, and enhance patient outcomes. OptimizeRx's initial focus was on leveraging electronic prescribing (eRx) systems to deliver financial messaging and patient support directly to physicians. This evolved into a broader platform offering brand awareness messaging, therapeutic support, and patient engagement tools. Their product suite includes a virtual patient support center, enabling access to sample vouchers, co-pay coupons, and other patient support resources through EMR and e-prescribe systems. They also offer brand support services, assisting pharmaceutical manufacturers in developing and implementing eRx media strategies. OptimizeRx operates a cloud-based Mobile Health Messenger platform, facilitating interactive health messaging for medication adherence and care coordination. Their HIPAA-compliant automated mobile messaging platform allows direct patient engagement, enhancing regimen compliance. The company also provides patient programs with treatment information, lifestyle trackers, and internet device connectivity. Headquartered in Rochester, Michigan, OptimizeRx continues to expand its offerings and market reach within the healthcare industry.
What Products and Services Does OPRX Offer?
- Connects life sciences organizations with healthcare providers and patients.
- Provides financial messaging services to deliver sample vouchers and co-pay coupons.
- Offers brand awareness and therapeutic support messaging services.
- Operates a cloud-based Mobile Health Messenger platform for medication adherence.
- Provides HIPAA-compliant automated mobile messaging for patient engagement.
- Offers patient programs with treatment and affordability information.
- Provides evidence-based physician engagement solutions using real-world data.
- Offers therapy initiation workflow focused on accelerating patient access to treatments.
How Does OPRX Make Money?
- Generates revenue by providing digital communication and engagement solutions to pharmaceutical manufacturers.
- Charges fees for delivering financial messaging and patient support services through EMR and e-prescribe systems.
- Earns revenue from brand awareness and therapeutic support messaging services.
- Offers subscription-based access to its Mobile Health Messenger platform.
What Industry Does OPRX Operate In?
OptimizeRx operates within the healthcare information services industry, which is experiencing significant growth due to the increasing adoption of digital health technologies and the growing need for improved patient engagement and medication adherence. The market is competitive, with companies offering various solutions for connecting pharmaceutical companies, healthcare providers, and patients. OptimizeRx differentiates itself through its focus on financial messaging, patient support, and brand awareness within the eRx ecosystem. The industry is expected to continue growing as healthcare providers and pharmaceutical companies seek to improve patient outcomes and reduce costs through digital solutions.
Who Are OPRX's Key Customers?
- Pharmaceutical manufacturers seeking to promote their products and improve patient adherence.
- Healthcare providers looking to access patient support resources and improve patient outcomes.
- Patients seeking information and support for their medications and health conditions.
FY2026 estForward Outlook
Wall Street analysts project OptimizeRx Corporation revenue of about $97.4M for fiscal 2026, with EPS near $0.94. The estimate reflects 5 contributing analysts.
ROE 5%Key Financial Metrics
Return on equity for OptimizeRx Corporation stands at 5.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.1%, showing how much profit it generates from its asset base. OPRX trades at a trailing price-to-earnings ratio of 16.30, below the Healthcare sector average of ~23x. Its free cash flow yield is 12.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 8/9Financial Health
OptimizeRx Corporation's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.46 places it in the grey zone, a middle ground that warrants monitoring.
OPRX Valuation & Market Position
With a $120M market cap, OptimizeRx Corporation sits in the micro-cap segment of the market. Relative to its peer group, OPRX's quantitative score of 87/100 is above the peer average of 62/100.
OPRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established presence in the digital health technology space.
- Strong relationships with pharmaceutical manufacturers and healthcare providers.
- Proprietary technology platform for delivering digital health solutions.
- HIPAA-compliant data security and privacy practices.
Bear Case
- Relatively small market capitalization compared to larger competitors.
- Dependence on the pharmaceutical industry for revenue.
- Limited geographic reach outside of the United States.
- Potential for regulatory changes affecting the pharmaceutical industry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
OPRX Latest News
-
Earnings Scheduled For May 12, 2026
benzinga · May 12, 2026
-
Earnings Scheduled For March 5, 2026
benzinga · Mar 5, 2026
-
Earnings Scheduled For November 6, 2025
benzinga · Nov 6, 2025
-
Earnings Scheduled For August 7, 2025
benzinga · Aug 7, 2025
OPRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OPRX.
Price Targets
Consensus target: $17.00
OPRX MoonshotScore
What does this score mean?
The MoonshotScore rates OPRX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Stephen L. Silvestro
CEO
Stephen L. Silvestro serves as the CEO of OptimizeRx Corporation. His background includes extensive experience in the healthcare technology sector, with a focus on driving innovation and growth. He has held leadership positions in various healthcare companies, where he was responsible for developing and implementing strategic initiatives to improve patient outcomes and streamline healthcare delivery. Silvestro's expertise spans areas such as digital health, data analytics, and healthcare IT. His career reflects a commitment to leveraging technology to address the challenges facing the healthcare industry.
Track Record: Under Stephen L. Silvestro's leadership, OptimizeRx has focused on expanding its digital health solutions and strengthening its relationships with pharmaceutical manufacturers and healthcare providers. Key achievements include the growth of the Mobile Health Messenger platform and the development of new patient engagement solutions. Silvestro has also overseen the company's efforts to enhance its data analytics capabilities and improve its HIPAA-compliant data security practices.
OptimizeRx Corporation Healthcare Stock: Key Questions Answered
What does the AI Score mean for OPRX?
OPRX holds an AI Score of 87/100 (Grade: A+). This is an educational research signal, not a buy or sell recommendation. OptimizeRx Corporation provides digital health solutions, connecting life sciences companies with healthcare providers and patients. Their platform facilitates communication and support, aiming …
What does OptimizeRx Corporation do?
OptimizeRx Corporation operates as a digital health technology company, providing solutions that connect pharmaceutical manufacturers, healthcare providers, and patients. Their platform facilitates the delivery of financial messaging, patient support, and brand awareness messaging through electronic medical record (EMR) and e-prescribing (eRx) systems.
What do analysts say about OPRX stock?
Analyst consensus on OptimizeRx Corporation (OPRX) reflects a mixed outlook, with some analysts highlighting the company's growth potential in the digital health market, while others express concerns about competition and regulatory risks. Key valuation metrics, such as the P/E ratio and market capitalization, are closely monitored to assess the company's financial performance and growth prospects.
What are the main risks for OPRX?
OptimizeRx Corporation faces several risks, including increasing competition in the digital health technology space, which could put pressure on pricing and market share. Data breaches and security vulnerabilities pose a threat to the company's reputation and financial stability, given the sensitive nature of patient data.
What are the key factors to evaluate for OPRX?
OptimizeRx Corporation (OPRX) holds an AI score of 87/100 (high). P/E: 16.3x vs the S&P 500's ~20-25x. Analysts target $17.00 (+166%). Not financial advice.
How frequently does OPRX data refresh on this page?
OPRX's price was last updated on Jul 27, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OPRX's recent stock price performance?
OptimizeRx Corporation (OPRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the digital health technology space. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OPRX overvalued or undervalued right now?
OptimizeRx Corporation (OPRX) trades at 16.3x earnings. Analysts target $17.00 (+166%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research OPRX before investing?
Before investing in OptimizeRx Corporation (OPRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are as of the latest available reporting period.
- Analyst opinions may vary.